October 14, 2015 | Pharma giant Pfizer has invested $10 million in the Israeli bio-medical company Protalix Biotherapeutics in exchange for a six percent share in the Karmiel-based company.
Protalix has also given Pfizer full commercial rights to the Gaucher disease treatment Elelyso in all countries except Brazil in exchange for $36 million cash. Since the companies’ first strategic agreement six years ago, Protalix has replaced its management and changed its business strategy, now lead by new CEO Moshe Manor. The company was founded in 1993 by biochemist Yoseph Shaaltiel, who developed the principle plant-based enzyme used in Elelyso.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments